Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients
- PMID: 9514541
- DOI: 10.1016/0168-8278(88)80015-1
Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients
Abstract
Background/aims: Insulin secretion is increased in cirrhotic patients without diabetes but decreased in cirrhotic patients with diabetes. Increased glucagon secretion is found in both groups. Our aim was to determine: 1) whether alterations in insulin secretion are due to changes in maximal secretory capacity or altered islet B-cell sensitivity to glucose, and 2) whether regulation of glucagon secretion by glucose is disturbed.
Methods: Insulin, C-peptide and glucagon levels were measured basally and during 12, 19 and 28 mmol/l glucose clamps, and in response to 5 g intravenous arginine basally and after 35 min at a glucose of 12, 19 and 28 mmol/l in 6 non-diabetic alcoholic cirrhotic patients, six diabetic alcoholic cirrhotic patients and six normal controls.
Results: Fasting insulin, and C-peptide levels were higher in cirrhotic patients than controls but not different between diabetic and non-diabetic patients. C-peptide levels at t=35 min of the clamp increased more with glucose concentration in non-diabetic cirrhotic patients than controls; there was little increase in diabetic cirrhotic patients. At a blood glucose of approximately 5 mmol/l the 2-5 min C-peptide response to arginine (CP[ARG]) was similar in all groups, but enhancement of this response by glucose was greater in non-diabetic cirrhotic patients and impaired in diabetic cirrhotic patients. Maximal insulin secretion (CP(ARG) at 28 mmol/l glucose) was 49% higher in the non-diabetic cirrhotic patients than controls (p<0.05); in diabetic cirrhotic patients it was 47% lower (p<0.05). The glucose level required for half-maximal potentiation of (CPARG) was not different in the three groups. Cirrhotic patients had higher fasting glucagon levels, and a greater 2-5-min glucagon response to arginine, which was enhanced by concomitant diabetes (p<0.001 vs controls). Suppression of plasma glucagon by hyperglycaemia was markedly impaired in diabetic cirrhotic patients (glucagon levels at 35 min of 28 mmol/l glucose clamp: diabetics, 139 x/divided by 1.25 ng/l, non-diabetic cirrhotic patients, 24 x/divided by 1.20, controls, 21 x/divided by 1.15, p<0.001). Suppression of arginine-stimulated glucagon secretion by glucose was also impaired in diabetic cirrhotic patients, and to a lesser extent in non-diabetic cirrhotic patients.
Conclusions: Insulin secretory abnormalities in diabetic and non-diabetic cirrhotic patients are due to changes in maximal secretory capacity rather than altered B-cell sensitivity to glucose. The exaggerated glucagon response to arginine in alcoholic cirrhotic patients is not abolished by hyperglycaemia/hyperinsulinaemia. In diabetic alcoholic cirrhotic patients, the inhibitory effect of glucose on basal glucagon secretion is also markedly impaired.
Similar articles
-
Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.Diabetes. 2002 Apr;51(4):951-7. doi: 10.2337/diabetes.51.4.951. Diabetes. 2002. PMID: 11916912 Clinical Trial.
-
Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation.Diabetes Care. 2001 Jul;24(7):1253-8. doi: 10.2337/diacare.24.7.1253. Diabetes Care. 2001. PMID: 11423511
-
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.J Clin Invest. 1984 Oct;74(4):1318-28. doi: 10.1172/JCI111542. J Clin Invest. 1984. PMID: 6384269 Free PMC article.
-
Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes".J Pediatr Endocrinol Metab. 2002 Apr;15 Suppl 1:493-501. J Pediatr Endocrinol Metab. 2002. PMID: 12017222 Review.
-
Clinical measures of islet function: usefulness to characterize defects in diabetes.Curr Diabetes Rev. 2008 May;4(2):129-45. doi: 10.2174/157339908784220714. Curr Diabetes Rev. 2008. PMID: 18473760 Review.
Cited by
-
Insulin resistance in clinical and experimental alcoholic liver disease.Ann N Y Acad Sci. 2015 Sep;1353(1):1-20. doi: 10.1111/nyas.12787. Epub 2015 May 21. Ann N Y Acad Sci. 2015. PMID: 25998863 Free PMC article. Review.
-
Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone.Lipids Health Dis. 2014 Jan 7;13:7. doi: 10.1186/1476-511X-13-7. Lipids Health Dis. 2014. PMID: 24397589 Free PMC article.
-
Hepatogenous diabetes: Knowledge, evidence, and skepticism.World J Hepatol. 2022 Jul 27;14(7):1291-1306. doi: 10.4254/wjh.v14.i7.1291. World J Hepatol. 2022. PMID: 36158904 Free PMC article. Review.
-
Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease.Metabolites. 2021 Mar 8;11(3):155. doi: 10.3390/metabo11030155. Metabolites. 2021. PMID: 33800465 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous